Clinical Trial Update: A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With TBR1-related Neurocognitive Disorder [Phase 1, Phase 2]

View source ↗

Summary

This entry describes a pilot, multicentre, open-label Phase 1/2 trial evaluating 24 months of lithium carbonate in patients with TBR1-related neurocognitive dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tbr1-related Neurocognitive Disorder

Drugs mentioned

• Lithium carbonate (Lithium carbonate)

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Proven Pathogenic or Probably Pathogenic TBR1 Variant | Phase 1, Phase 2 | Status: RECRUITING